Table 5.

Adverse events

System Organ Class/ Preferred Term	Placebo (N=6) n (%)	AZD7594 200 μg (N=7), n (%)	AZD7594 400 μg (N=7), n (%)	AZD7594 1600 μg (N=7), n (%)	Total AZD7594 (N=21), n (%)	All subjects (N=27), n (%)
Subjects with any AE	1 (16.7)	3 (42.9)	1 (14.3)	1 (14.3)	5 (23.8)	6 (22.2)
Respiratory, thoracic and mediastinal disorders	0	3 (42.9)	0	0	3 (42.9)	3 (11.1)
Dry throat	0	1 (14.3)	0	0	1 (4.8)	1 (3.7)
Nasal congestion	0	1 (14.3)	0	0	1 (4.8)	1 (3.7)
Oropharyngeal pain	0	1 (14.3)	0	0	1 (4.8)	1 (3.7)
Infections and infestations	0	0	1 (14.3)	0	1 (4.8)	1 (3.7)
Folliculitis	0	0	1 (14.3)	0	1 (4.8)	1 (3.7)
Metabolism and nutritional disorders	1 (16.7)	0	0	0	0	1 (3.7)
Gout	1 (16.7)	0	0	0	0	1 (3.7)
Nervous system disorders	0	0	0	1 (14.3)	1 (4.8)	1 (3.7)
Presyncope	0	0	0	1 (14.3)	1 (4.8)	1 (3.7)

Abbreviations: AE, adverse event; N, number of subjects randomized to each treatment or overall; n (%), number of subjects in each category expressed as a percentage of N.